ActiQs
Mer att utforska

Verktyg för dig

Kombinationer Mina bevakningar

För professionella

Ämnesregister Källregister API & data
ActiQs / Forskning
PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vatalanib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

14 träffar
Bibliografisk träff 2014-06-18

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD.

Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-014-2499-4
Bibliografisk träff 2013-05-23

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA, Alliance for Clinical Trials in Oncology.

Invest New Drugs · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-013-9978-z
Bibliografisk träff 2013-04-19

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

Brander D, Rizzieri D, Gockerman J, Diehl L, Shea TC, Decastro C, Moore JO, Beaven A.

Leuk Lymphoma · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.3109/10428194.2013.784969
Bibliografisk träff 2012-08-21

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.

Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL, Tumour and Angiogenesis Research Group.

Br J Cancer · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1038/bjc.2012.369
Bibliografisk träff 2012-06-05

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).

Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ.

Pharmacogenomics J · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1038/tpj.2012.23
Bibliografisk träff 2011-05-26

Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).

Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WEE.

Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1093/annonc/mdr255